# Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

> **NCT04938297** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Rituximab, Lenalidomide, Zanubrutinib
- **DRUG:** Lenalidomide, Zanubrutinib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04938297
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-26
- **Primary completion:** 2022-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04938297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04938297, "Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04938297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*